| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Licochalcone B, a naturally occuring chalcone compound isolated from the root of Glycyrrhiza inflate, is an inhibitor of phosphorylation of NF-kappaB p65 in LPS signaling pathway. It also inhibits amyloid β (Aβ42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ions.
| ln Vitro |
Aβ42 aggregation is inhibited and Aβ42 pre-fibril formation is fragmented by licochalcone B (IC50: 2.16 μM) [1]. In SH-SY5Y cells, licochalcone B (0–12 μM, 48 h) decreases ROS generation and safeguards the cell culture medium H2O2. causes cellular apoptosis. In RAW264.7 cells, licochalcone B (10 μM, 1 h) suppresses the activation of NF-κB triggered by LPS [2]. Licochalcone B (0–20 μM, 24 or 48 h) suppresses the development of human NSCLC cells, while licochalcone B (10 μM, 1 h) inhibits LPS-induced NF-κB p65 serine 276 phosphorylation [3].
|
|---|---|
| ln Vivo |
Licochalcone B (1–25 mg/kg, gavage) reduces the oxidative stress and hepatotoxicity that CCl4[5] causes in mice.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: RAW264.7 Cell Tested Concentrations: 10. µM Incubation Duration: 1 hour Experimental Results: Inhibits phosphorylation of NF-κB at serine 276 but not at serine 536. |
| Animal Protocol |
Animal/Disease Models: CCl4[5] induced mice
Doses: 1, 5, 25 mg/kg Route of Administration: po (oral gavage). Experimental Results: SOD and GSH levels increased, and GSSG levels diminished. |
| References |
[1]. Cao Y, et al. Licochalcone B, a chalcone derivative from Glycyrrhiza inflata, as a multifunctional agent for the treatment of Alzheimer's disease. Nat Prod Res. 2018 Oct 22:1-4.
[2]. Jun-ichi Furusawa, et al. Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol. 2009 Apr;9(4):499-507. [3]. Ha-Na Oh, et al. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Phytomedicine. 2019 Oct;63:153014. [4]. Qiang Li, et al. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7-NLRP3 interaction. EMBO Rep. 2022 Feb 3;23(2):e53499. [5]. Teng H, et al. Hepatoprotective effects of licochalcone B on carbon tetrachloride-induced liver toxicity in mice. Iran J Basic Med Sci. 2016 Aug;19(8):910-915. |
| Molecular Formula |
C16H14O5
|
|---|---|
| Molecular Weight |
286.28
|
| Exact Mass |
286.0841
|
| CAS # |
58749-23-8
|
| Related CAS # |
58749-23-8;
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
OC1=CC=C(/C=C/C(C2=CC=C(O)C(O)=C2OC)=O)C=C1
|
| InChi Key |
IOBDWJXFMVMVKI-XBXARRHUSA-N
|
| InChi Code |
InChI=1S/C16H14O5/c1-21-16-12(7-9-14(19)15(16)20)13(18)8-4-10-2-5-11(17)6-3-10/h2-9,17,19-20H,1H3/b8-4+
|
| Chemical Name |
(E)-1-(3,4-dihydroxy-2-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
|
| Synonyms |
LicoB Lico-B Lico BLicochalcone-B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~291.08 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
